Updated efficacy and safety from the global phase II NP28673 ...
文章推薦指數： 80 %
Clinical trial identification: NCT01801111 [NP28673] and NCT01871805 [NP28761]. Legal entity responsible for the study: F. Hoffmann-La Roche Ltd ...
延伸文章資訊
- 1Pooled overall survival and safety data from the pivotal phase ...
Objectives: A pooled analysis of two open-label phase II studies of alectinib (NP28673 [NCT018011...
- 2Pooled Analysis of CNS Response to Alectinib in Two Studies ...
... two single-arm phase II studies (NP28761 and NP28673; ClinicalTrials.gov identifiers: NCT0187...
- 3A Study of Alectinib (RO5424802) in Participants With Non ...
ClinicalTrials.gov Identifier: NCT01801111. Recruitment Status : Completed. First Posted : Februa...
- 4A Study of Alectinib (RO5424802) in ... - Cancer Trial Results
NCT01801111 - A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Wh...
- 5Exposure-response analysis of alectinib in crizotinib-resistant ...
Alectinib demonstrated robust efficacy in a pooled analysis of two single-arm, open-label phase I...
